Medical Advocates
Pegylated Interferons
  Hepatitis C Treatment Adverse Events

General Adverse Events
 Cryoglobulinemia
 Diabetes
 Fatigue
 Insulin Resistance
 Cardiovascular Disorders
 Mental Disorders
 Digestive Disorders
 Neurological Disorders
Ocular Disorders
 Respiratory Disorders
 Sarcoidosis

  
Peg Interferons HCV Main Page Main New/Newsworthy  Home Page

Last Update:  July 31, 2016
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Adverse Events  
     
          Journal Papers, Abstracts, and Commentaries
 
 
Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers (BTMs) in HIV/HCV Co-Infected Patients.
 Bedimo R, Kang M, Tebas P,  et al
AIDS Res Hum Retroviruses. 2015 Oct 23.
 Abstract

Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report.
 Gamal N, Brodosi L, Misciali C,  et al
Ann Hepatol. 2014 Mar-Apr;13(2):293-6.
 Abstract

Risk factors for infection during treatment with peginterferon alfa and ribavirin
for chronic hepatitis C.
 Roomer R, Hansen BE, Janssen HL, de Knegt RJ
Hepatology. 2010 Jul 29.
 Abstract

FULL-TEXT ARTICLE
 Weight loss, leukopenia and thrombocytopenia associated with sustained virologic
response to Hepatitis C treatment.
 Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC.
Int J Med Sci. 2010 Jan 22;7(1):36-
 Paper

Tongue Hyperpigmentation Resulting From Peginterferon Alfa and Ribavirin Combination Therapy:
A Case Report.
 de Moraes PC, Noce CW, Thomaz LA
 J Am Dent Assoc. 2009 Nov;140(11):1377-1379
 Abstract

A case of overwhelming postsplenectomy infection (OPSI) with chronic hepatitis type C during
peginterferon/ribavirin combination therapy.
 Okamura S, Sakai T, Yoshikai H, et al
Nippon Shokakibyo Gakkai Zasshi. 2009 Mar;106(3):411-7.
 Abstract

FULL TEXT PDF ARTICLE
 Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.
 Arase Y, Suzuki F, Suzuki Y, et al  
Intern Med. 2007;46(22):1827-32.
Paper
CryoglobulinemiaCardinoma
     

          Journal Papers, Abstracts, and Commentaries
 
  Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment
of hepatitis C with peginterferon alfa.
 Batisse D, Karmochkine M, Jacquot C, et al
Eur J Gastroenterol Hepatol. 2004 Jul;16(7):701-3.
 Abstract

Cryoglobulinemia
     

          Journal Papers, Abstracts, and Commentaries
 
  Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment
of hepatitis C with peginterferon alfa.
 Batisse D, Karmochkine M, Jacquot C, et al
Eur J Gastroenterol Hepatol. 2004 Jul;16(7):701-3.
 Abstract
Diabetes
     
          Journal Papers, Abstracts, and Commentaries
 
 
Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis.
Popescu C, Popescu GA, Arama V.
 J Gastrointestin Liver Dis. 2013 Mar;22(1):101-4.
 Abstract

FULL-TEXT PDF ARTICLE
 Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN
alone, induced type 1 diabetes in a patient with chronic hepatitis C.
 Ogihara T, Katagiri H, Yamada T, et al 
Intern Med. 2009;48(16):1387-90
 Paper
Fatigue
     
            Conference Reports, Abstracts, and Posters 
 
  High prevalence of fatigue and depression in HIV/Hepatitis C co-infected patients
treated with pegylated Interferon/Ribavirin
K L N Jones, S J Ferrando, A H Talal, et al
(15IAC)
 Abstract
Insulin Resistance
     
          Journal Papers, Abstracts, and Commentaries
 
 
Insulin Resistance and Geographical Origin: Major Predictors of Liver Fibrosis
and Response to Peginterferon and Ribavirin in HCV-4.
 Moucari R, Ripault MP, Martinot-Peignoux M, et al
Gut. 2009 Aug 10.
Abstract

Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic
hepatitis C patients.
Dai CY, Huang JF, Hsieh MY,
 J Hepatol. 2009 Feb 6
 Abstract
Cardiovascular Disorders
     
          Journal Papers, Abstracts, and Commentaries
 
  A case of cardiac sarcoidosis occurring during combination therapy by IFN alpha
and ribavirin for chronic hepatitis C
Iwashita M, Maeda T, Tagami A,  et al
Nippon Shokakibyo Gakkai Zasshi. 2010 Aug;107(8):1319-27
 Abstract
Mental Disorders
     

          Journal Papers, Abstracts, and Commentaries
 
  Risk Factors and Clinical Characteristics of the Depressive State Induced by Pegylated Interferon Therapy in Patients with Hepatitis C Virus Infection: A Prospective Study.
Kawase K, Kondo K, Saito T, et al
Psychiatry Clin Neurosci. 2016 Jul 29
 Abstract
 

 

            Conference Reports, Abstracts, and Posters 
 
  High prevalence of fatigue and depression in HIV/Hepatitis C co-infected patients
treated with pegylated Interferon/Ribavirin
K L N Jones, S J Ferrando, A H Talal, et al
 (I5IAC)
 Abstract

Digestive System Disorders
     

     Peg Interferon/Ribavirin

          Journal Papers, Abstracts, and Commentaries

 
Pegylated Interferon plus Ribavirin Combination Therapy for Chronic Hepatitis C with High Viral Load
of Serum Hepatitis C Virus RNA, Genotype 1b, Discontinued on Attaining Sustained Virological
Response at Week 16 after Onset of Acute Pancreatitis.
 Kim SR, Imoto S, Mita K, Taniguchi M, et al 
Digestion. 2009 Feb 25;79(1):36-39.
Abstract
 

Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic
hepatitis C.
Leung Y, Urbanski SJ, Schindel L, Myers RP.
Can J Gastroenterol. 2006 Oct;20(10):661-3.
 Abstract
Neurological Disorders
     
          Journal Papers, Abstracts, and Commentaries
 
  Seizures in Patients with Chronic Hepatitis C Treated with NS3/4A Protease Inhibitors: Does Pharmacological Interaction Play a Role?
 Milazzo L, Falvella FS, Magni C,et al
Pharmacology. 2013 Oct 31;92(5-6):235-237z
 Abstract

Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients
with HCV.
 Briani C, Chemello L, Zara G, et al
 Neurology. 2006 Sep 12;67(5):781-5.
Abstract
Ocular Disorders
     
          Journal Papers, Abstracts, and Commentaries
 
 
Outcome of Retinopathy in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin.
 Mehta N, Murthy UK, Kaul V, et al 
Dig Dis Sci. 2009 Feb 26. 
Abstract
 
UK prospective study of change in visual function in patients treated with Peginterferon alpha
for hepatitis C.
 Malik NN, Sheth HG, Ackerman N, et al
 Br J Ophthalmol. 2007 Oct 25
 Abstract
 
Ocular complications of hepatitis C treatment
Sauer A, Lenoble P, Bader P, et al
J Fr Ophtalmol. 2007 Sep;30(7)
Abstract
 
Retinopathy in a patient with hepatitis C treated with pegylated interferon and ribavirin:
case report.
 Avila MP, Freitas AM, Isaac DL, et al
Arq Bras Oftalmol. 2006 Mar-Apr;69(2):255-9.
 Abstract
Respiratory Disorders
     
          Journal Papers, Abstracts, and Commentaries
 
  Simultaneous Occurrence of Pleural Effusion and Interstitial Pneumonitis After Treatment with
Pegylated Interferon for Hepatitis C Virus Infection.
 Ji F, Li Z, Xue H,  et al
South Med J. 2010 Dec 31.
 Abstract
Sarcoidosis
     

         Journal Papers, Abstracts, and Commentaries
 
 
Pulmonary sarcoidosis associated with pegylated interferon in the treatment of chronic
hepatitis C.
 Ubina-Aznar E, Fernandez-Moreno N, Rivera-Irigoin R, et al 
Gastroenterol Hepatol. 2005 Oct;28(8):450-2
 Abstract

Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic
hepatitis C: a case report and review of the literature.
 Hurst EA, Mauro T. 
Arch Dermatol. 2005 Jul;141(7):865-8.
Abstract

Peg Interferons HCV Main Page Main New/Newsworthy  Home Page

Pegylated Interferons
Hepatitis C Treatment Adverse Events